Surrogate tissue analysis : genomic, proteomic and metabolomic approaches /: genomic, proteomic and metabolomic approaches. (2006)

• Record Type: Book
• Further Information: Note: Edited by Michael E. Burczynski and John C. Rockett.
• Other Names: Burczynski, Michael E; Rockett, John C
• Contents: INTRODUCTION TO SURROGATE TISSUE ANALYSIS; Introduction to Surrogate Tissue Analysis, J.C. Rockett and M.E. Burczynski; Introduction; Areas That Could Benefit from Surrogate Tissue Analysis; Challenges to the Use of Surrogate Tissues; Summary; References; ; GENOMIC APPROACHES; Impact of Sample Handling and Preparation on Gene Signatures as Exemplified for Transcriptome Analysis of Peripheral Blood, J.L. Schultze, S. Debey, R. Pillai, and T. Zander; Introduction; Application of Standards to Genomic Technologies; Different Cell and RNA Preparation Methods from Whole Blood: An Introduction; Comparison of Different Preparation Techniques of Whole Blood Samples; Distinct Gene Expression Patterns in Peripheral Blood after Delayed Preparation; Comparison of the QIAamp Method to PBMC; Gene Expression Profiling of Whole Blood; Requisites for Future Clinical Transcriptome Studies of Peripheral Blood; Conclusions and Future Directions; Acknowledgments; References; ; Blood Genomic Fingerprints of Brain Diseases, Y. Tang, D.L. Gilbert, T.A. Glauser, A.D. Hershey, A. Lu, R. Ran, H. Xu, and F.R. Sharp; Introduction; Methods; Results; Discussion; Acknowledgments; References; ; Transcriptional Profiling of Peripheral Blood in Oncology, M.E. Burczynski; Introduction; Surrogate Tissue Profiling in Translational Medicine and Oncology Drug Development; Class Discovery and Class Distinction in Surrogate Tissue Profiling Studies; Relevance of Peripheral Blood in Assessment of Patients with Solid Tumors; Pharmacogenomic Analysis of PBMCs in Renal Cell Carcinoma: A Case Study; Other Surrogate Tissue Profiling Studies in Oncology; Issues and Caveats with PBMC Profiling in Oncology Studies; Summary; Acknowledgments; References; ; Blood-Derived Transcriptomic Profiles as a Means to Monitor Levels of Toxicant Exposure and the Effects of Toxicants on Inaccessible Target Tissues, J.C. Rockett; Introduction; Blood Gene Expression as a Biomarker of Whole-Body Toxicant Exposure; Blood as a Surrogate Tissue for Monitoring Gene Expression Changes in an Inaccessible Target Tissue; Challenges to the Use of Blood as a Surrogate Tissue; Summary; References; ; Spermatozoal RNAs as Surrogate Markers of Paternal Exposure, G.C. Ostermeier and S.A. Krawetz; Introduction; RNA in Sperm: Initial Observations; Transcript Survey Techniques; Defining the Normal Fertile Male; Data Mining Sperm mRNAs; Sperm as a Surrogate Tissue; Application; Acknowledgments; References; ; PROTEOMIC APPROACHES; Proteomic Analysis of Surrogate Tissues: Mass Spectrometry-Based Profiling of the Circulatory Proteome for Cancer Detection and Stratification, E.F. Petricoin III, K.R. Calvo, J. Wulfkuhle, and L.A. Liotta; Clinical Cancer Biomarkers: Is the Pipeline Dried Up?; A Rich Potential Source of Candidate Biomarkers in the Low-Molecular-Weight Realm; Points to Consider for Mass Spectrometry-Based Profiling Studies; Biomarker Amplification via Carrier Protein Sequestration: Underpinnings of the Mass Spectral Information; Concluding Remarks and a View to the Future; Acknowledgments; References; ; Lymphocyte Integrins: Potential Surrogate Biomarkers for Evaluation of Endometrial Receptivity, K.V.R. Reddy, S.M. Gupta, and P.K. Meherji; Introduction; Endometrial Biomarkers in Implantation; Integrins and Endometrial Function; Embryonic Integrins and Implantation; Integrins and Reproductive Dysfunction; Integrins and Infertility; Role of Peripheral Blood Lymphocytes in Endometrial Function; Correlation between Endometrial Cell and Peripheral Lymphocyte Integrins; Summary and Conclusions; Acknowledgments; References; ; Nipple Aspirate Fluid to Diagnose Breast Cancer and Monitor Response to Treatment, E. Sauter; Introduction; Initial Studies of NAF Focus on Feasibility; Studies Evaluating Cells in NAF; Studies Evaluating Extracellular Fluid in NAF; NAF as a Tool to Investigate the Presence of Mutagens in the Breast; Effect of Botanicals on the Breast; Assessing Response to Chemopreventive Agents; Summary; References; ; METABOLOMICS AND OTHER APPROACHES; Metabonomics: Metabolic Profiling and Pattern Recognition Analysis of Body Fluids and Tissues for Characterization of Drug Toxicity and Disease Diagnosis, J.L. Griffin and N.J. Waters; Overview; Introduction; High-Throughput Metabolic Profiling in Drug Toxicology; Mass Spectrometry, Metabonomics, and Toxicology; Disease Diagnosis; Correlation of Metabonomics with Other -omic Technologies; Cryoprobe Technology; High-Resolution Magic Angle Spinning 1 H NMR Spectroscopy; Drug Development; Metabonomics In Vivo; Conclusions; References; ; Comprehensive Metabolomic Profiling of Serum and Cerebrospinal Fluid: Understanding Disease, Human Variability, and Toxicity, S. Ritchie; Introduction; Analytical Methodologies; Searching for Biomarkers in a Sea of Human Variability; Comprehensive Metabolomic Profile Analysis of Human Serum; Comprehensive Metabolomic Profile Analysis of Human Cerebrospinal Fluid; Application of Metabolomics to the Discovery of Toxicologic Markers; Concluding Remarks; References; ; Lipidomic Analysis of Plasma and Tissues: Lipid-Derived Mediators of Inflammation and Markers of Disease, C.B. Clish and C.N. Serhan; Introduction; Membrane Architecture/Structure-Function; Lipid Signals and Autocoids in Disease; Comparative Mediator-Lipidomic Profiling of Engineered Experimental Animals; Novel Extracellular Biosignals from Lipids: Pathways of Inflammation-Resolution; Biomarker Lipidomics; Summary; Acknowledgments; References; ; Molecular Detection and Characterization of Circulating Tumor Cells and Micrometastases in Solid Tumors, R.A. Ghossein, H. Al-Ahmadie, and S. Bhattacharya; Introduction; PCR Technology; Applications to Specific Tumor Types; Future Trends; References; ; Methylation Profiling of Tumor Cells and Tumor DNA in Blood, Urine, and Body Fluids for Cancer Detection and Monitoring, I.H.N. Wong; Introduction; DNA Hypermethylation and Cancer Progression; Concurrent Hypermethylation, Transcriptional Silencing, and Loss of Function; Methylation Profiles in Circulating Tumor Cells Isolated from Blood of Patients with Cancer and Biological Implications; Methylation Profiling of Circulating Tumor DNA in Plasma and Serum from Patients with Cancer; Combinatorial Analyses of DNA Hypermethylation in Plasma/Serum and Conventional Protein Tumor Markers in Serum; Molecular Monitoring of Human Cancers in Blood and Prognostic Implications; Methylation Profiling of Tumor Cells and Tumor DNA in Urine from Patients with Cancer; Methylation Profiling of Tumor Cells and Tumor DNA in Other Body Fluids from Patients with Cancer; Qualitative and Quantitative Analyses of Aberrant Methylation Changes: Sensitivity and Specificity; High-Throughput Methods for Methylation Profiling in Cancer Cells and the Selection of Target Genes as Epigenetic Markers in Blood and Body Fluids; References; ; FUTURE CONSIDERATIONS FOR SURROGATE TISSUE PROFILING; Regulatory and Technical Challenges in Incorporating Surrogate Tissue Profiling Strategies into Clinical Development Programs, J.L. Oestreicher, M.J. Cahilly, D.P. Mounts, M.Z. Whitley, L.A. Speicher, W.L. Trepicchio, and M.E. Burczynski; Introduction; The Clinical Question of Interest; Pharmacogenomic Study Logistics and Clinical Trial Design; Transitioning the Clinical Pharmacogenomic Laboratory into a Regulatory Compliant Environment; Assurance of Data Integrity Generated in Clinical Pharmacogenomic Studies: Establishing Validated Databases and Data Transfers; Regulatory Considerations and Trial Design Issues during Pharmacogenomic Marker Development; Summary; References; ; Considerations in the Economic Assessment of the Value of Molecular Profiling, S.C. Stallings, A.J. Sinskey, and S.N. Finkelstein; Introduction; Health Economics, Pharmacoeconomics, and Overcoming Inertia in the Adoption of Pharmacogenomic Strategies; Economic Evaluations of Molecular Profiling in Clinical Practice; Molecular Profiling in Drug Development; Conclusion; References; ; The Impact and Challenges of Pan-Omic Approaches in Pharmaceutical Discovery and Development, W.D. Pennie, J.L. Colangelo, and M.P. Lawton; Introduction; The Genomics Sciences: Predictive and Investigative Opportunities; Oncology and Drug-Induced Vasculitis: Examples of Progress and Practical Considerations in Applying Genomics Techniques; Moving Forward; References; ; Current and Future Aspects of Surrogate Tissue Analysis, M.E. Burczynski; Introduction; Translatio
• Publisher Details: Boca Raton : CRC Press
• Publication Date: 2006
• Extent: 1 online resource (306 pages), illustrations (some color)
• Subjects: 572.8; Biochemical markers; Genomics; Proteomics; Marqueurs biologiques; Génomique; Protéomique; SCIENCE -- Life Sciences -- Molecular Biology; Biochemical markers; Genomics; Proteomics; Biomarkers -- analysis; Genetic Techniques; Genomics -- methods; Metabolism; Proteomics -- methods; Electronic books
• Languages: English
• ISBNs: 1420038095; 9781420038095; 0849328403; 9780849328404
• Related ISBNs: 9780849328404; 0849328403
• Notes: Note: Includes bibliographical references and index.; Note: Print version record.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.